Advertisment

Sanofi Boosts Research Spending: Aims for 12 Potential Blockbuster Drugs

author-image
Ayanna Amadi
New Update
NULL

Sanofi Boosts Research Spending: Aims for 12 Potential Blockbuster Drugs

Advertisment

Amid increasing investor pressure, French drugmaker Sanofi has announced the development of 12 drugs, which are expected to generate over $1 billion in annual sales. This announcement is a part of Sanofi's strategic plan to boost its pipeline and strengthen its position in the pharmaceutical market by significantly increasing research spending.

Advertisment

Sanofi's Investor R&D Event

Sanofi recently hosted an Investor R&D Event in New York, where they provided updates and insights into their innovative pipeline and new growth drivers. The company’s primary focus is on developing and leveraging its leadership in immunology across all other therapeutic areas. During the event, Sanofi plans to showcase a pipeline of 12 potential blockbuster assets in immunology and vaccines, which is expected to lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025. This momentum is set to create the greatest pipeline in the company's history.

Focus on 12 Blockbuster Drug Candidates

Advertisment

Sanofi's focus is on 12 blockbuster drug candidates for its immunology pipeline. These 12 drugs include 9 medicines and vaccines with a potential for generating 2 billion to 5 billion euros in peak sales. Additionally, there are 3 'pipeline-in-a-product' assets that could potentially generate more than 5 billion euros in peak sales.

Bolstering New Medicines Pipeline

Sanofi has laid out ambitious plans to bolster its pipeline of new medicines. This move is aimed at justifying its decision to invest its funds into key programs rather than increasing its operating profit margin. Sanofi forecasts more than €10 billion in annual sales from recent launches and future medicines by 2030.

Advertisment

Identification of High Potential Drugs

Sanofi has shared high-level details of its plan to deliver 12 blockbuster medicines, each capable of generating 2 billion or more in sales. The company has identified three drugs with peak sales potential of more than 5 billion euros, namely amlitelimab, frexalimab, and SAR441566. Sanofi also named nine other medicines and vaccines that could generate peak sales of more than 2 billion euros.

R&D Strategy and Future Forecasts

Sanofi unveiled its revamped pipeline and R&D strategy aiming to deliver 12 blockbuster medicines, each capable of generating 2 billion or more in sales. Sanofi CEO Paul Hudson and new R&D chief Houman Ashrafian defended the company's decision to reduce earnings forecasts for 2024 and ramp up spending for more research studies of new medicines.

This strategic move by Sanofi is a testament to the company's commitment to driving innovation and delivering high-quality medicines. By focusing on strengthening their drug pipeline, Sanofi aims to secure its position in the global pharmaceutical market and deliver significant returns for its investors.

Advertisment
Chat with Dr. Medriva !